NCT01767896View on ClinicalTrials.gov

Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

1,020

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

ASP7374

subcutaneous (sc)

BIOLOGICAL

approved egg-derived TIV

subcutaneous (sc)

Trial Locations (3)

Unknown

Kansai

Kantou

Kyushu

All Listed Sponsors
lead

UMN Pharma Inc.

INDUSTRY

NCT01767896 - Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine | Biotech Hunter | Biotech Hunter